Optimizing Glucagon for Medical Use: Better Diabetes and Obesity Drug Candidates

Systematic optimization of the native glucagon sequence produced analogs with improved stability, selectivity, and pharmacokinetics for potential dual GLP-1/glucagon receptor agonist obesity and diabetes drugs.

Chabenne, Joseph R et al.·Journal of diabetes science and technology·2010·
RPEP-015962010RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Systematic optimization of the native glucagon sequence produced analogs with improved stability, selectivity, and pharmacokinetics for potential dual GLP-1/glucagon receptor agonist obesity and diabetes drugs.

Key Numbers

How They Did This

research study.

Why This Research Matters

Relevant for peptide research.

The Bigger Picture

Advances peptide research.

What This Study Doesn't Tell Us

See abstract.

Questions This Raises

  • ?Further research needed.

Trust & Context

Key Stat:
Key finding Systematic optimization of the native glucagon sequence produced analogs with improved stability, selectivity, and pharmacokinetics for potential dual
Evidence Grade:
emerging evidence.
Study Age:
Published in 2010.
Original Title:
Optimization of the native glucagon sequence for medicinal purposes.
Published In:
Journal of diabetes science and technology, 4(6), 1322-31 (2010)
Database ID:
RPEP-01596

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What was studied?

Optimizing Glucagon for Medical Use: Better Diabetes and Obesity Drug Candidates

What was found?

Systematic optimization of the native glucagon sequence produced analogs with improved stability, selectivity, and pharmacokinetics for potential dual GLP-1/glucagon receptor agonist obesity and diabetes drugs.

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-01596·https://rethinkpeptides.com/research/RPEP-01596

APA

Chabenne, Joseph R; DiMarchi, Maria A; Gelfanov, Vasily M; DiMarchi, Richard D. (2010). Optimization of the native glucagon sequence for medicinal purposes.. Journal of diabetes science and technology, 4(6), 1322-31.

MLA

Chabenne, Joseph R, et al. "Optimization of the native glucagon sequence for medicinal purposes.." Journal of diabetes science and technology, 2010.

RethinkPeptides

RethinkPeptides Research Database. "Optimization of the native glucagon sequence for medicinal p..." RPEP-01596. Retrieved from https://rethinkpeptides.com/research/chabenne-2010-optimization-of-the-native

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.